Short Interest in Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV) Drops By 91.3%

Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV) was the target of a significant decrease in short interest in August. As of August 14th, there was short interest totaling 140 shares, a decrease of 91.3% from the July 30th total of 1,608 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily volume of 1,984 shares, the days-to-cover ratio is presently 0.1 days.

Mosaic ImmunoEngineering Stock Performance

Mosaic ImmunoEngineering stock remained flat at $0.06 on Tuesday. The company’s stock had a trading volume of 11 shares, compared to its average volume of 1,073. Mosaic ImmunoEngineering has a fifty-two week low of $0.05 and a fifty-two week high of $1.05. The stock has a market capitalization of $441,640.00, a price-to-earnings ratio of -0.68 and a beta of -0.82. The firm has a 50-day moving average of $0.49 and a two-hundred day moving average of $0.57.

Mosaic ImmunoEngineering (OTCMKTS:CPMV) last released its earnings results on Friday, August 14th. The company reported ($0.02) earnings per share for the quarter.

Mosaic ImmunoEngineering Company Profile

Mosaic ImmunoEngineering (OTCMKTS:CPMV) is a development-stage biotechnology company focused on advancing immunotherapies and vaccine candidates through its proprietary nanoparticle platform. The company leverages virus-like particles derived from the cowpea mosaic virus (CPMV) to serve as both antigen carriers and immune stimulators, aiming to enhance the magnitude and durability of immune responses. By engineering these plant-based VLPs to display target antigens or adjuvant properties, Mosaic ImmunoEngineering seeks to create differentiated candidates for oncology indications and infectious disease prevention.

Operating out of the United States, Mosaic ImmunoEngineering is currently in preclinical stages of development.